Repository
How to publish
Resources
FAQs

Show simple item record

PsABIOnd study and edaily substudy design: long-term effectiveness and safety of guselkumab and il-17 inhibitors in routine clinical practice in patients with psoriatic arthritis

dc.contributor.authorSiebert, S.
dc.contributor.authorBehrens, F.
dc.contributor.authorLubrano, E.
dc.contributor.authorMartin, N.
dc.contributor.authorSharaf, M.
dc.contributor.authorContré, C.
dc.contributor.authorTheander, E.
dc.contributor.authorQueiro Silva, Rubén 
dc.contributor.authorZimmermann, M.
dc.contributor.authorGossec, L.
dc.date.accessioned2023-05-18T08:22:16Z
dc.date.available2023-05-18T08:22:16Z
dc.date.issued2023
dc.identifier.citationRheumatology and Therapy, 10(2), p. 489-505 (2023); doi:10.1007/s40744-022-00518-w
dc.identifier.issn2198-6576
dc.identifier.urihttp://hdl.handle.net/10651/68191
dc.description.sponsorshipPsABIOnd is sponsored by Janssen. DAMAN Health developed the eDaily app, which was sponsored by Janssen. Janssen also funded the journal’s Rapid Service Fee.
dc.format.extentp. 489-505
dc.language.isoeng
dc.relation.ispartofRheumatology and Therapy
dc.rights© 2022 Los autores
dc.rightsCC Reconocimiento 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScopus
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85145205933&doi=10.1007%2fs40744-022-00518-w&partnerID=40&md5=7de59851828d9ab45df5add9a77ace49
dc.titlePsABIOnd study and edaily substudy design: long-term effectiveness and safety of guselkumab and il-17 inhibitors in routine clinical practice in patients with psoriatic arthritis
dc.typejournal article
dc.identifier.doi10.1007/s40744-022-00518-w
dc.relation.publisherversionhttp://dx.doi.org/10.1007/s40744-022-00518-w
dc.rights.accessRightsopen access
dc.type.hasVersionVoR


Files in this item

untranslated
Name:
s40744-022-00518-w.pdf
Size:
661.3Kb
Format:
PDF
Description:
Versión de la editorial

This item appears in the following Collection(s)

Show simple item record

© 2022 Los autores
This item is protected with a Creative Commons License